Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

This study is testing a combination of two drugs — cabozantinib (a targeted therapy) and dostarlimab (an immunotherapy) — for people with recurrent gynecologic carcinosarcoma, a rare and aggressive cancer that can arise in the uterus, ovaries, or other gynecologic organs. **You may be eligible if:** - You have been diagnosed with gynecologic carcinosarcoma confirmed by biopsy - You have received at least one prior chemotherapy regimen for this cancer - You have measurable or evaluable disease - You are in reasonably good health (ECOG performance status 0–2) - You are 18 or older with adequate organ function (blood counts, liver, kidneys) **You may NOT be eligible if:** - You have uncontrolled high blood pressure or active liver disease - You have significant bleeding problems or blood clotting disorders - You have active autoimmune disease requiring treatment - You are pregnant or breastfeeding - You have had prior treatment with cabozantinib or a similar drug Talk to your doctor to see if this trial is right for you.